SCHEMBL25375170

SCHEMBL25375170

COc1ccc(C(OC[C@H]2C[C@@H](n3ccc(=O)[nH]c3=O)[C@H](OC)[C@@H]2O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TYMP P19971 1/20 0.41
DUT P33316 5/20 0.39
P2RY14 Q15391 3/20 0.38
SLC6A11 P48066 4/20 0.36
SLC6A1 P30531 2/20 0.36
P2RY2 P41231 3/20 0.34
P2RY6 Q15077 2/20 0.34
NT5E P21589 1/20 0.34
P2RY4 P51582 2/20 0.33
MEN1 O00255 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
KMT2A Q03164 1/20 0.33
SLC6A12 P48065 1/20 0.33
SLC6A13 Q9NSD5 1/20 0.33
HSP90AA1 P07900 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25376281 0.85 DUT (0.38) TYMPDUTP2RY14SLC6A11SLC6A1
SCHEMBL1052781 0.82 TYMP (0.41) TYMPDUTP2RY14SLC6A11SLC6A1
SCHEMBL1050827 0.82 TYMP (0.41) TYMPDUTP2RY14SLC6A11SLC6A1
SCHEMBL19549038 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL20828930 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL6284695 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL3721728 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL19709160 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL6284697 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4
SCHEMBL19709158 0.81 TYMP (0.53) TYMPP2RY14P2RY2P2RY6P2RY4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12636301-B2 5′-modified carbocyclic ribonucleotide derivatives and methods of use SANEGENE BIO USA INC. (US) 2026-05-26 US disclosed
EP-4482845-A1 5'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USE Sanegene Bio USA Inc. (US) 2025-01-01 EP disclosed
US-20230346819-A1 5'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USE SANEGENE BIO USA INC. 2023-11-02 US disclosed
WO-2023164464-A1 5'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USE SANEGENE BIO USA INC. (US) 2023-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230346819-A1 5'-MODIFIED CARBOCYCLIC RIBONUCLEOTIDE DERIVATIVES AND METHODS OF USE NSUN2, RNMT, RNGTT TYMP 12/4885DUT 20/4885P2RY14 1400/4885
US-12636301-B2 5′-modified carbocyclic ribonucleotide derivatives and methods of use NSUN2, RNASE1, RNASEL TYMP 113/4885DUT 134/4885P2RY14 2968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.